Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mericitabine

Next Previous
Drug Profile

Mericitabine

Alternative Names: R-7128; RG 7128; RG7320; RO 5024048

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmasset
  • Developer Roche
  • Class Antivirals; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 12 Feb 2016 Roche terminates a phase II trial in Hepatitis C in USA, Australia, Austria, Brazil, Canada, France, Germany, Italy, Mexico, New Zealand, Poland, Puerto Rico, Slovakia, Spain and United Kingdom due to decrease in percentage of participants (NCT01168856)
  • 28 Jan 2015 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-experienced) in Australia, Canada, USA, Brazil, Mexico, Germany, France, Spain, Puerto Rico, Poland, New Zealand, Slovakia, United Kingdom, Austria, Italy (PO)
  • 28 Jan 2015 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Germany, France, Italy, Puerto Rico, Canada, USA, Australia, Poland, Austria, United Kingdom, Spain, New Zealand (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top